Pan, F., Zhang, T., Zhang, Yh. et al. Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome., Chin. J. Integr. Med. 15, 216–219 (2009). https://doi.org/10.1007/s11655-009-0216-7
Feng Pan, Tao Zhang, Yong-hua Zhang, et al. Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome[J]. Chinese Journal of Integrative Medicine, 2009,15(3):216-219.
Pan, F., Zhang, T., Zhang, Yh. et al. Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome., Chin. J. Integr. Med. 15, 216–219 (2009). https://doi.org/10.1007/s11655-009-0216-7DOI:
Feng Pan, Tao Zhang, Yong-hua Zhang, et al. Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome[J]. Chinese Journal of Integrative Medicine, 2009,15(3):216-219. DOI: 10.1007/s11655-009-0216-7.
Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome
摘要
To study the clinical effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome (D-IBS) and its possible mechanism. A total of 120 patients were assigned to two groups using stratified block randomization
80 in the intervention group and 40 in the control group. To the intervention group the TXYF granule was given at one package each time
twice a day; the control group was treated with Miyarisan three times a day
two tablets each time. The course of treatment was 4 weeks for both groups. The total efficacy in them was compared
and data of scoring on stool (Bristol method)
abdominal pain
abdominal distension
and mental condition were collected before treatment and 2 and 4 weeks after treatment. The activation of mast cells (MCs) of six patients chosen from each group was detected as well before and after treatment. No significant difference between the two groups in terms of the total efficacy or the scores of symptoms before and after treatment was found (P>0.05). The number of activated MCs was decreased in the intervention group after treatment
showing significant difference as compared with that before treatment as well as with that in the control group after treatment (P<0.01). TXYF is an effective preparation for the treatment of D-IBS. It can quickly lessen abdominal pain and distention
improve the property of stool
and improve mental tension and depression in patients. Its mechanism of action might be through the adjustment of MCs activation to decrease visceral hypersensitivity.
Abstract
To study the clinical effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome (D-IBS) and its possible mechanism. A total of 120 patients were assigned to two groups using stratified block randomization
80 in the intervention group and 40 in the control group. To the intervention group the TXYF granule was given at one package each time
twice a day; the control group was treated with Miyarisan three times a day
two tablets each time. The course of treatment was 4 weeks for both groups. The total efficacy in them was compared
and data of scoring on stool (Bristol method)
abdominal pain
abdominal distension
and mental condition were collected before treatment and 2 and 4 weeks after treatment. The activation of mast cells (MCs) of six patients chosen from each group was detected as well before and after treatment. No significant difference between the two groups in terms of the total efficacy or the scores of symptoms before and after treatment was found (P>0.05). The number of activated MCs was decreased in the intervention group after treatment
showing significant difference as compared with that before treatment as well as with that in the control group after treatment (P<0.01). TXYF is an effective preparation for the treatment of D-IBS. It can quickly lessen abdominal pain and distention
improve the property of stool
and improve mental tension and depression in patients. Its mechanism of action might be through the adjustment of MCs activation to decrease visceral hypersensitivity.
Halpert AD, Thomas AC, Hu Y, Morris CB, Bangdiwala SI, Drossman DA. A survey on patient educational needs in irritable bowel syndrome and attitudes toward participation in clinical research. J Clin Gastroenterol 2006;40:37–43.
Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in Guangdong province. Natl Med J China (Chin) 2004;84:14–16.
Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006;15:237–241.
Zheng XY, ed. Guiding principle of Clinical Research on new drugs of traditional chinese medicine. Beijing: China Medic-Pharmaceutical Sciences and Technology Publishing House; 2002:139–143.
Gong ZJ, ed. The technology of preparation and dyeing histopathology. 1st ed. Shanghai: Shanghai Scientific and Technical Publishers; 1994:267–272.
Li W, Wen HM, Cui XB, Zhang FC, Dong J. Chemical constituents in rhizome of Atractylodes macrocephala. Chin Tradit Herb Drugs (Chin) 2007;38:1460–1462.
Wang, Guo HZ, Huo CH, Shi QW, Ye M, Bi KS, et al. Chemical constituents in root of Paeonia lactiflora. chin Tradit Herb Drugs (Chin) 2007;38:972–976.
Li W, Zheng TZ, Qu SY, Tian ZF, Qiu XQ, Ding GH, et al. Effect of tangerine peel on gastric emptying and small intestinal propulsive function in mice. Pharmac Clin Chin Materia Med (Chin) 2002;18:22–23.
Xu HZ, Xie JQ, Shi B, Zhang T. The effects of Wenzhongjianpi Decoction on the mast cell in the colon mucosa of rats with diarrhea irritable bowel syndrome. J Jiangxi Univ Tradit Chin Med (Chin) 2007;19:58–60.